Concortis is a corporate sponsor for PEGS Boston: the essential protein engineering summit, May 5 -9, 1014 at Seaport World Trade Center.
NEW! Concortis is pleased to announce the addition of PNU-159682 to its extensive portfolio of payloads. PNU-159682 is a doxorubicin derivative displaying thousand fold higher cytotoxicity than its congener. PNU-159682 is available in three formats:
- Free drug three toxin, catalog Nr. D4001
- PNU-159682-linker through custom synthesis
- As ADC through our in-house conjugation services
Concortis is a biotechnology company creating next generation biotherapeutics using our proprietary conjugation technologies and novel drug delivery systems, which allow us to build small molecule drugs into a variety of biologics with enhanced efficacies and reduced side-effects. The company focuses on oncology and metabolic diseases. We have multiple programs in early stage developments. Our next generation platforms include ADC technology.
Sorrento Therapeutics completed acquisition of Concortis Biosystems in December 2013. With the acquisition, Sorrento adds Concortisā proprietary cytotoxic payloads as well as C-lockĀ® and K-lockĀ® conjugation technologies that allow for site-specific toxin conjugation to the antibody. These new technologies may improve the overall stability and potency of the ADC. First-generation conjugation technologies lead to inconsistent drug-antibody ratios, which result in a heterogeneous mixture of ADCs. This variability has been a constraining factor in unlocking the full therapeutic potential for current-generation ADCs.